ES2639757T3 - Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales - Google Patents

Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales Download PDF

Info

Publication number
ES2639757T3
ES2639757T3 ES11764989T ES11764989T ES2639757T3 ES 2639757 T3 ES2639757 T3 ES 2639757T3 ES 11764989 T ES11764989 T ES 11764989T ES 11764989 T ES11764989 T ES 11764989T ES 2639757 T3 ES2639757 T3 ES 2639757T3
Authority
ES
Spain
Prior art keywords
alkyl
amino
group
halogen
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11764989T
Other languages
English (en)
Inventor
Graham Cumming
Narenda Kumar B. Patel
Bryan T. Forrest
Yong Liu
Sze-Wan Li
Peter Brent Sampson
Louise G. Edwards
Heinz W. Pauls
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2010/000518 external-priority patent/WO2010115279A1/en
Application filed by University Health Network filed Critical University Health Network
Application granted granted Critical
Publication of ES2639757T3 publication Critical patent/ES2639757T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

Un procedimiento para preparar un compuesto de espiroindolinona representado por la siguiente Fórmula Estructural: **Fórmula** o una sal del mismo, que comprende la etapa de hacer reaccionar un compuesto de indolinona representado por la siguiente Fórmula Estructural: **Fórmula** con una base y un compuesto de indazol representado por la siguiente Fórmula Estructural: **Fórmula** en la que: cada uno de Ra y Rb es independientemente -H, halógeno, -C(O)OR1, -C(O)R1, -C(S)R1, -OC(O)R1-, -C(O)NR1R2, -C(S)NR1R2, -OC(O)NR1R2, -S(O)R1, -S(O)2R1, -SO3R1, -SO2NR1R2, -OR1, -SR1, -NR1R2, -NR2C(O)R1, -NR2S(O)R1, -NR2C(O)OR1, -NR2C(O)ONR1R2, -N(R2)C(O)NR1R2, -NR2SO2NR1R2, -NR2SO2R1; -NO2, -CN, -NCS; o dos grupos Ra en orto tomados conjuntamente forman -O-[CH2]p-O-, -S-[CH2]p-S- o -[CH2]q-; o un grupo alifático C1-10 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, nitro, ciano, -N(R21)2, -C(O)N(R21)2, -C(O)N(R21)2, -NR21C(O)R21, -SO2R22, -SO2N(R21)2, -NR21SO2R22, -NR21C(O)OR21, -OC(O)N(R21)2, -NR21C(O)N(R21)2, -NR21C(O)ON(R21)2, -NR21SO2N(R21)2, -OR21, -SR21, halogenoalcoxi C1-10, -C(O)R21, -C(O)OR21 y -OC(O)R21; o (alquilen C0-10)-Ar1, en la que Ar1 es un grupo arilo C6-14 o un grupo heteroarilo de 5-14 miembros, cada uno opcional e independientemente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, nitro, ciano, alquilo C1-10, halogenoalquilo C1-10, (halogenoalcoxi C1-10)alquilo C1-10, (alcoxi C1-10)alquilo C1-10, hidroxialquilo C1-10, aminoalquilo C1-10, (alquil C1-10-amino)alquilo C1-10, (dialquil C1-10 -amino)alquilo C1-10, -N(R21)2, -C(O)N(R21)2, -C(O)N(R21)2, -NR21C(O)R21, -SO2R22, -SO2N(R21)2, -NR21SO2R22, -NR21C(O)N(R21)2, -NR21C(O)ON(R21)2, -NR21SO2N(R21)2, -OR21, -SR21, halogenoalcoxi C1-10, -C(O)R21, -C(O)OR21, -OC(O)R21, fenilo y heteroarilo de 5-6 miembros, en los que dicho fenilo y dicho heteroarilo de 5-6 miembros están cada uno independiente y opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, hidroxi, nitro, ciano, amino, alquilo C1-3, halogenoalquilo C1-3, alcoxi C1-3 y halogenoalcoxi C1-3; cada R1 es independientemente: i) hidrógeno; ii) un grupo arilo C6-14 o un grupo heteroarilo de 5-14 miembros, cada uno opcional e independientemente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, -NO2, -CN, -NCS, alifático C1-C10, (alquilen C1-10)-Ar10, -C(O)OR10, -C(O)R10, -C(S)R10, -OC(O)R10, -C(O)N(R11)2, -C(S)N(R11)2, -OC(O)N(R11)2, -S(O)R12, -S(O)2R12, -SO3R12, -SO2N(R11)2, -OR10, -SR10, -N(R11)2, -NR11C(O)R10, -NR11S(O)R12, -NR11C(O)OR12, -N(R11)C(O)N(R11)2, -NR11SO2N(R11)2 y -NR11SO2R12; o iii) un grupo alifático C1-10 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, -NO2, -CN, -NCS, Ar10, -C(O)OR10, -C(O)R10, -C(S)R10, -OC(O)R10, -15 C(O)N(R11)2, -C(S)N(R11)2, -OC(O)N(R11)2, -S(O)R12, -S(O)2R12, -SO3R12, -SO2N(R11)2, -OR10, -SR10, -N(R11)2, -NR11C(O)R10, -NR11S(O)R12, -NR11C(O)OR12, -N(R11)C(O)N(R11)2, -NR11SO2N(R11)2 y -NR11SO2R12, a condición de que R1 sea distinto de hidrógeno cuando Ra o Rb sea -S(O)R1, -S(O)2R1, -SO3R1, -NR2S(O)R1 o -NR2SO2R1; y cada R2 es independientemente -H o alquilo C1-C6, o, tomado conjuntamente con NR1, forma un grupo heterocíclico no aromático opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en >=O, >=S, halógeno, nitro, ciano, hidroxi, alquilo C1-6, halogenoalquilo C1-6, hidroxialquilo C1-6, 25 amino, alquil C1-6-amino, dialquil C1-6-amino, aminoalquilo C1-6, (alquil C1-6-amino)alquilo C1-6, (dialquil C1-6-amino)alquilo C1-6, (fenil)alquilo C1-6, (heteroaril de 5-6 miembros)alquilo C1-6, alcoxi C1-6, halogenoalcoxi C1-6, alquil C1-6-carboniloxi, alcoxi C1-6-carbonilo, alquil C1-6-carbonilo, fenilo y heteroarilo de 5-6 miembros; R3 es -H, halógeno, alquilo C1-6 o halogenoalquilo C1-6; R4 es -H, alquilo C1-6, fenilo, -C(O)(alquilo C1-6), -C(O)(fenilo), -C(O)O(alquilo C1-6), -C(O)O(fenilo), -S(O)2(alquilo C1-6) o -S(O)2(fenilo), en los que cada alquilo en los grupos representados por R4 está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, hidroxi, nitro, ciano, amino, -C(O)NH2, fenilo, heteroarilo de 5-6 miembros, alcoxi C1-6, alquil C1-6-amino, 35 dialquil C1-6-amino y halogenoalcoxi C1-6, y en los que cada fenilo en los grupos representados por R4 está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, hidroxi, nitro, ciano, amino, alquilo C1-6, halogenoalquilo C1-6, alcoxi C1-6 y halogenoalcoxi C1-6; R6 es hidrógeno, halógeno, nitro, ciano, R', -OR, -SR, -N(R)2, -C(O)R, -C(O)OR, -OC(O)R, -C(O)N(R)2, -OC(O)N(R)2, -NRC(O)R, -NRC(O)OR, -SOR', -SO2R', -SO3R', -SO2N(R)2, -NRS(O)R', -NRSO2R', -NRC(O)N(R)2, -NRC(O)ON(R)2, o -NRSO2N(R)2; cada R10 es independientemente: i) hidrógeno; ii) un grupo arilo C6-14 o un grupo heteroarilo de 5-14 miembros, cada uno opcional e independientemente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, nitro, ciano, hidroxi, alquilo C1-10, halogenoalquilo C1-10, (halogenoalcoxi C1-10)alquilo C1-10, 50 (alcoxi C1-10)alquilo C1-10, hidroxialquilo C1-10, aminoalquilo C1-10, (alquil C1-10-amino)alquilo C1-10, (dialquil C1-10-amino)alquilo C1-10, (fenil)alquilo C1-10, (heteroaril de 5-6 miembros)alquilo C1-10, amino, alquil C1-10-amino, dialquil C1-10-amino, alcoxi C1-10, halogenoalcoxi C1-10, alquil C1-10-carboniloxi, alcoxi C1-10-carbonilo y alquil C1-10-carbonilo; o iii) un grupo alquilo C1-10 opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, nitro, ciano, hidroxi, halogenoalquilo C1-10, alcoxi C1-10, halogenoalcoxi C1-10, amino, alquil C1-10-amino, dialquil C1-10-amino, alquil C1-10-carboniloxi, alcoxi C1-10-carbonilo, alquil C1-10-carbonilo y fenilo, estando dicho fenilo opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo consistente en halógeno, hidroxi, nitro, ciano, amino, alquilo C1-60 3, halogenoalquilo C1-3, alcoxi C1-3 y halogenoalcoxi C1-3;
ES11764989T 2010-04-06 2011-04-06 Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales Active ES2639757T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32132910P 2010-04-06 2010-04-06
US32133210P 2010-04-06 2010-04-06
PCT/CA2010/000518 WO2010115279A1 (en) 2009-04-06 2010-04-06 Kinase inhibitors and method of treating cancer with same
PCT/CA2011/000387 WO2011123947A1 (en) 2010-04-06 2011-04-06 Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones

Publications (1)

Publication Number Publication Date
ES2639757T3 true ES2639757T3 (es) 2017-10-30

Family

ID=44761967

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11764988.9T Active ES2603613T3 (es) 2010-04-06 2011-04-06 Inhibidores de quinasa y su uso en el tratamiento del cáncer
ES11764989T Active ES2639757T3 (es) 2010-04-06 2011-04-06 Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES11764988.9T Active ES2603613T3 (es) 2010-04-06 2011-04-06 Inhibidores de quinasa y su uso en el tratamiento del cáncer

Country Status (25)

Country Link
US (9) US8921545B2 (es)
EP (2) EP2556071B1 (es)
JP (1) JP5442906B2 (es)
KR (1) KR101782668B1 (es)
CN (1) CN102892766B (es)
AU (1) AU2011238384B2 (es)
BR (1) BR112012025496B1 (es)
CY (1) CY1118610T1 (es)
DK (1) DK2556071T3 (es)
EA (1) EA023173B1 (es)
ES (2) ES2603613T3 (es)
HR (1) HRP20161498T1 (es)
HU (1) HUE030651T2 (es)
IL (1) IL221556A (es)
LT (1) LT2556071T (es)
ME (1) ME02545B (es)
MX (1) MX2012011516A (es)
NZ (1) NZ602350A (es)
PL (1) PL2556071T3 (es)
PT (1) PT2556071T (es)
SG (1) SG183875A1 (es)
SI (1) SI2556071T1 (es)
SM (1) SMT201600430B (es)
TW (1) TWI516262B (es)
WO (2) WO2011123947A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2235004A4 (en) * 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物
WO2015054781A1 (en) * 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
US11608334B2 (en) 2017-02-08 2023-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CN108947961B (zh) * 2017-05-18 2021-06-04 四川大学 吲唑类衍生物及其制备方法和用途
WO2019046949A1 (en) 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
CA3137191A1 (en) 2019-04-24 2020-10-29 University Health Network Crystal form s4 of the plk4 inhibitor (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate
BR112022011052A2 (pt) * 2019-12-06 2022-08-16 Univ Health Network Tratamento para leucemia mieloide aguda ou síndrome mielodisplásica
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN112250614B (zh) 2020-10-20 2022-02-01 苏州大学 3-螺三元环吲哚酮衍生物的合成方法
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
TW202300485A (zh) * 2021-03-02 2023-01-01 大陸商上海齊魯製藥研究中心有限公司 Plk4抑制劑及其用途
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
US20260015351A1 (en) * 2022-06-30 2026-01-15 Axonis Therapeutics, Inc. Methods and compounds for inhibiting mkk7 enzymes
EP4688750A1 (en) 2023-04-06 2026-02-11 Pfizer Inc. Substituted indazole propionic acid derivative compounds and uses thereof as ampk activators

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69734521T9 (de) 1996-08-23 2006-12-07 Sugen, Inc., South San Francisco Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7429609B2 (en) 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
US20070167488A1 (en) 2003-12-16 2007-07-19 Leo Pharma A/S Novel therapeutic use
US20050211590A1 (en) 2004-03-26 2005-09-29 Mcclure George K Protective cover for medical devices
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7309787B2 (en) * 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2007109026A2 (en) 2006-03-15 2007-09-27 The Trustees Of Columbia University In The City Of New York Pten compositions and methods for detecting breast cancer
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2181108A2 (en) 2007-06-12 2010-05-05 Boehringer Ingelheim International GmbH 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
EP2205241B1 (en) 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
WO2009065232A1 (en) 2007-11-20 2009-05-28 University Health Network Cancer diagnostic and therapeutic methods that target plk4/sak
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
EP2262499B1 (en) * 2008-03-11 2016-12-21 University Health Network Mk-0557 for use in the treatment of cancer
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
EP2303260A1 (en) 2008-06-16 2011-04-06 Tigris Pharmaceuticals, Inc. Methods for determining sensitivity to aminoflavones
DE102008040187A1 (de) * 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
HUE043194T2 (hu) 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
US8263596B2 (en) 2012-09-11
US20180282306A1 (en) 2018-10-04
WO2011123947A1 (en) 2011-10-13
US20180105511A1 (en) 2018-04-19
US10358436B2 (en) 2019-07-23
US8921545B2 (en) 2014-12-30
US20170226088A1 (en) 2017-08-10
ES2603613T3 (es) 2017-02-28
EP2556071A4 (en) 2013-09-04
ME02545B (me) 2017-02-20
EP2556071A1 (en) 2013-02-13
JP2013523784A (ja) 2013-06-17
NZ602350A (en) 2014-05-30
US9907800B2 (en) 2018-03-06
SI2556071T1 (sl) 2016-12-30
WO2011123947A8 (en) 2011-12-22
PL2556071T3 (pl) 2017-02-28
WO2011123946A8 (en) 2011-12-08
US20120264800A1 (en) 2012-10-18
EP2556070B1 (en) 2017-06-07
EP2556071B1 (en) 2016-08-17
US9796703B2 (en) 2017-10-24
US20150133677A1 (en) 2015-05-14
HUE030651T2 (en) 2017-05-29
CY1118610T1 (el) 2017-07-12
EA023173B1 (ru) 2016-04-29
US20130096301A1 (en) 2013-04-18
DK2556071T3 (en) 2016-12-12
EA201270752A1 (ru) 2013-04-30
SG183875A1 (en) 2012-10-30
KR101782668B1 (ko) 2017-09-27
BR112012025496A2 (pt) 2020-08-18
US8481533B2 (en) 2013-07-09
MX2012011516A (es) 2013-03-08
CN102892766A (zh) 2013-01-23
US10077255B2 (en) 2018-09-18
JP5442906B2 (ja) 2014-03-19
US20110263598A1 (en) 2011-10-27
PT2556071T (pt) 2016-11-22
US20160045511A1 (en) 2016-02-18
LT2556071T (lt) 2017-01-25
CN102892766B (zh) 2015-05-20
EP2556070A1 (en) 2013-02-13
IL221556A (en) 2015-04-30
BR112012025496B1 (pt) 2021-02-23
WO2011123946A1 (en) 2011-10-13
AU2011238384B2 (en) 2015-02-19
US9139563B2 (en) 2015-09-22
US20140045838A1 (en) 2014-02-13
US9579327B2 (en) 2017-02-28
TW201134471A (en) 2011-10-16
TWI516262B (zh) 2016-01-11
SMT201600430B (it) 2017-01-10
KR20130108065A (ko) 2013-10-02
AU2011238384A1 (en) 2012-09-27
HRP20161498T1 (hr) 2016-12-16
EP2556070A4 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
ES2639757T3 (es) Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
CO2021000808A2 (es) Agente profiláctico o terapéutico para atrofia muscular espinal
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
ES2431163T3 (es) Inhibidores de PIM quinasa y métodos para su uso
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR099824A1 (es) Compuestos bicíclicos
AR107912A1 (es) Inhibidores de ret
AR082029A1 (es) Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
EA201071112A1 (ru) ПРОИЗВОДНЫЕ ПОЛИЗАМЕЩЁННЫХ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ИХ В ТЕРАПИИ
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
CY1118739T1 (el) Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
AR079814A1 (es) Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
AR068846A1 (es) Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
CO6351793A2 (es) \"derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
NZ715847A (en) New indole and pyrrole derivatives useful as bcl-2 inhibitors, a process for their preparation and pharmaceutical compositions containing them
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
ECSP13012416A (es) Derivados heterocíclicos fusionados como moduladores s1p